Binding molecules

What is this patent about?

’877 is related to the field of antibody engineering and the production of therapeutic proteins in transgenic animals. Traditionally, monoclonal antibodies are complex tetramers requiring both heavy and light chains, which complicates manufacturing and limits the creation of multi-specific formats. The background context involves the discovery of heavy chain-only antibodies (HCAbs) in camelids and the desire to replicate this simplified structure using human-derived sequences to avoid immunogenicity while maintaining high binding affinity.

The underlying idea behind ’877 is that a functional, diverse, and high-affinity immune response can be generated in a transgenic mammal using a simplified heterologous VH heavy chain locus. By intentionally deleting the CH1 domain from the constant region, the invention forces the biological system to produce antibodies that do not require a light chain for stability or secretion. This insight allows the animal’s natural immune machinery to perform VDJ recombination and somatic hypermutation on single-domain binding units, resulting in matured human VH domains that are soluble and stable as monomers.

The claims of ’877 focus on a method for producing a soluble, antigen-specific VH binding domain by utilizing a transgenic rodent. The process requires a specific genetic construct where the heavy chain locus contains V, D, and J segments linked to a constant region that lacks a functional CH1 domain. The independent claim specifically covers the steps of immunizing this rodent, allowing for in vivo affinity maturation, and subsequently cloning the resulting VDJ sequence from an antibody-producing cell to produce the isolated single-domain binder.

In practice, the invention works by bypassing the need for complex phage display libraries to find high-affinity binders. Instead, the transgenic rodent serves as a living bioreactor that optimizes the human VH domains in response to an antigen challenge. Once the rodent’s B-cells have refined the antibody through natural selection, the genetic information for the antigen-binding domain is harvested. These domains can then be expressed in simpler microbial systems like E. coli or yeast, which are far more cost-effective than the mammalian cell cultures required for standard four-chain antibodies.

This approach differentiates itself from prior art by ensuring that the resulting antibodies are entirely devoid of light chains from the outset, preventing the solubility issues typically associated with isolated human VH domains. Unlike camelid-derived VHH fragments, which may be recognized as foreign by the human immune system, the ’877 patent enables the production of fully human sequences that have undergone natural maturation. Furthermore, the absence of the CH1 domain acts as a molecular trigger that ensures only heavy chain-only species are secreted, streamlining the recovery of potent, single-domain therapeutic candidates.